Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in <i>BRCA</i>-mutated <i>HER2</i>-negative metastatic or advanced breast cancer: a network meta-analysis

← Back

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

Figure 8. Forest plots comparing acceptability of treatment discontinuation and QoL. (A) Treatment discontinuation; (B) QoL.